A. ÖZDİL, A. ÇAKAN, U. ÇAĞIRCI, K. TURHAN, A. G ERGÖNÜL, A. VERAL

C-Met immunoreactivity in operated stage I non-small cell lung cancer

Amaç: Bu çalışmada opere edilmiş erken evre küçük hücreli dışı akciğer karsinomlu (KHDAK) hastalarda, c-Met immünreaktivitesi ile sağkalım arasındaki korelasyon ve hepatosit büyüme faktörünün (HGF) prognoz üzerindeki etkisi araştırılmıştır. Gereç ve Yöntem: Evre IA veya IB KHDAK tanısıyla opere edilen 70 hasta retrospektif olarak incelendi. Patoloji preparatları c-Met immünreaktivitesinin belirlenmesi için tekrar değerlendirildi. Kesitlerdeki normal bronş epiteli pozitif kontrol grubu, primer antikor tarafından boyanmayan kesitler ise negatif kontrol grup olarak kabul edildi. C-met immünreaktivitesi boyanma skorlarına göre belirlendi. Bulgular: C-met immünreaktivitesi ile klinik ve patolojik faktörler arasında istatistiksel olarak anlamlı fark bulunmadı. Büyük hücreli karsinomlar çalışma dışında bırakılarak yapılan analizler adenokarsinomlarda skuamöz hücreli karsinomlara göre c-Met immünreaktivitesinin daha yüksek olduğunu gösterdi ve fark istatistiksel olarak anlamlı idi. C-met immünreaktivitesinin prognostik etkisini tahmin etmek için yapılan analizlerde gerek hastalıksız sağkalım (p=0.499) gerekse uzun dönem sağkalım (p=0.261) açısından anlamlı fark saptanmadı. C-met immünreaktivitesi ile adenokarsinom ve skuamöz hücreli karsinom gruplarının sağkalımı arasındaki fark da istatistiksel olarak anlamlı değildi. Sonuç: KHDAKda HGF ekspresyonu ve serum seviyeleri c-Met immünreaktivitesine göre daha güçlü prognostik marker olarak gözükmektedir. Bu nedenle bu prognostik faktörler ile ilgili daha kapsamlı çalışmalara gereksinim vardır.

Opere edilmiş evre I küçük hücreli dışı akciğer karsinomlu olgularda c-Met immünreaktivitesi: Prognostik bir belirteç mi?

Aim: In this study we evaluated the correlation between c-Met immunoreactivity and survival, thus the effect of hepatocyte growth factor (HGF) on prognosis, in operated early-stage non-small cell lung carcinoma (NSCLC) patients. Materials and Methods: Seventy patients who underwent resection for stage IA or IB NSCLC were examined retrospectively. Pathological preparations were evaluated to investigate c-Met immunoreactivity. Those with normal bronchial epithelium in the sections were used as positive control group and the sections of those who had not been stained by primary antibody were regarded as the negative control group. C-Met immunoreactivities were determined according to scores of staining. Results: There were no significant differences between c-Met immunoreactivity and clinicopathological factors. The analysis after exclusion of large cell carcinoma cases showed that c-Met immunoreactivity was higher in adenocarcinomas than in squamous cell carcinomas and the difference was statistically significant. Survival analysis to estimate the prognostic significance of c-Met immunoreactivity showed no significant differences for both disease- free (p=0.499) and long-term survival (p=0.261). The difference between c-Met immunoreactivity and survival for the adenocarcinoma and squamous cell carcinoma groups was not significant. Conclusion: It seems that HGF expression and serum HGF levels appeared to be stronger prognostic markers than c-Met immunoreactivity for NSCLC, therefore detailed studies were needed regarding these prognostic factors.

PDF

___

1. Reed CE, Silvestri GA. Diagnosis and staging of lung cancer. In: Shields TW, LoCicero III J, Ponn RB, Rusch VW (eds). General Thoracic Surgery, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;1534-47.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94.
3. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies. Eur Respir J 2009;33(6):1485-97.
4. Siegfried JM, Weissfeld LA, Singh Kaw P, Weyant RJ, Testa JR, Landreneau RJ. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997;57(3):433-9.
5. Takanami I, Tanana F, Hashizume T, et al. Hepatocyte growth-factor and c-met: hepatocyte growth-factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Onco 1996;53(5):392-7.
6. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22(4):309-25.
7. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225(1):1-26
8. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis. Cancer Sci 2007;98(7):1006-13.
9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111(6):1710-7.
10. DAmico TA, Brooks KR, Joshi MBM, et al. Serum protein recurrence in patients with early-stage lung cancer after resection. Ann Thorac Surg 2006;81(6):1982-7.
11. Sawabata N, Ohta M, Takeda S, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2003;74(1):174-9.
12. Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with non-small cell lung cancer. Am J Clin Oncol 1998;21(3):284-6.
13. Okuda K, Sasaki H, Yukie H, Yano M, Fuji Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99(11):2280-5.
14. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non- small cell lung carcinomas. Br J Cancer 1996;74(12):1862-8.
15. Chen J, Lin T, Chow K, et al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol 2006;34(3):264-73.
16. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87(10):1063-9.
17. Harvey P, Warn A, Newman P, Perry LJ, Ball RY, Warn RM. Immunoreactivity for hepatocyte growth factor scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996;180(4):389-94.
18. Tsao M, Liu N, Chen J, et al. Differential expression of c-met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998;20(1):1-16.
19. Yi S, Tsao M. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000;2(3):226-34.
20. Siegfried JM, Luketich JD, Stabile LP, Christie N, Land SR. Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest 2004;125(5Suppl):116-9.
21. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 1998;66(6):1915-8.
22. Taniguchi T, Kitamura M, Arai K, et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 1997;75(5):673-7.
23. Yamashita J, Ogawa M, Beppu T. Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res Commun Chem Pathol Pharmacol 1993;82(2):249-52.
24. Harpole DH Jr, Herndon JE II, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I non-small cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76(5):787-96.